why choose us

First received: July 24, 2022

Clinical Trial: Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Nonalcoholic Fatty Liver
Osteoporosis, Postmenopausal

Study Type: INTERVENTIONAL


Official Title: Effect of Anti-osteoporotic Medications on Hepatic Steatosis and Fibrosis of Women With Postmenopausal Osteoporosis and Nonalcoholic Fatty Liver Disease

Brief Summary: Nonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode. NAFLD affects approximately 25% of the worldwide population. NAFLD refers to a phenotypic spectrum, including steatosis, inflammation and fibrosis, which can lead to cirrhosis and hepatocellular carcinoma in a minority of patients. However, despite its high prevalence, morbidity and mortality, as well as the…

Read more